JP2008535475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535475A5 JP2008535475A5 JP2007556317A JP2007556317A JP2008535475A5 JP 2008535475 A5 JP2008535475 A5 JP 2008535475A5 JP 2007556317 A JP2007556317 A JP 2007556317A JP 2007556317 A JP2007556317 A JP 2007556317A JP 2008535475 A5 JP2008535475 A5 JP 2008535475A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- composition
- therapeutic agent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 229920001184 polypeptide Polymers 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 238000002703 mutagenesis Methods 0.000 claims description 4
- 231100000350 mutagenesis Toxicity 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 20
- 229940124597 therapeutic agent Drugs 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 239000002616 MRI contrast agent Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010051920 Glomerulonephropathy Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65426105P | 2005-02-18 | 2005-02-18 | |
| PCT/US2006/005615 WO2006112930A2 (en) | 2005-02-18 | 2006-02-17 | Q3 sparc deletion mutant and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535475A JP2008535475A (ja) | 2008-09-04 |
| JP2008535475A5 true JP2008535475A5 (enExample) | 2009-04-02 |
Family
ID=37000156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556317A Pending JP2008535475A (ja) | 2005-02-18 | 2006-02-17 | Ｑ３ｓｐａｒｃ欠失変異体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7332568B2 (enExample) |
| EP (1) | EP1869077A2 (enExample) |
| JP (1) | JP2008535475A (enExample) |
| CN (1) | CN101160321A (enExample) |
| AU (1) | AU2006237613A1 (enExample) |
| CA (1) | CA2598510C (enExample) |
| WO (1) | WO2006112930A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070122465A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) * | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| JP5590882B2 (ja) | 2006-06-26 | 2014-09-17 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ） |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| AU2008240117B2 (en) * | 2007-04-13 | 2013-12-05 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| JP2011515078A (ja) * | 2008-03-01 | 2011-05-19 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法 |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| JP2011516609A (ja) * | 2008-04-14 | 2011-05-26 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ｓｐａｒｃ抗炎症活性及びその使用 |
| WO2010065954A2 (en) * | 2008-12-05 | 2010-06-10 | Abraxis Bioscience, Llc | Sparc binding peptides and uses thereof |
| AU2013228006B2 (en) * | 2008-12-05 | 2016-05-12 | Abraxis Bioscience, Llc | Albumin binding peptide-mediated disease targeting |
| AU2009322126B2 (en) * | 2008-12-05 | 2013-06-20 | Abraxis Bioscience, Llc | Albumin binding peptide-mediated disease targeting |
| KR20110139256A (ko) * | 2009-03-11 | 2011-12-28 | 아브락시스 바이오사이언스, 엘엘씨 | Ｓｐａｒｃ 혈관형성 영역과 사용방법 |
| WO2011035274A1 (en) * | 2009-09-18 | 2011-03-24 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| AU2011261240A1 (en) | 2010-06-03 | 2013-01-10 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| CA2801184A1 (en) * | 2010-06-03 | 2011-12-08 | Abraxis Bioscience, Llc | Peripheral blood sparc binding antibodies and uses thereof |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| EP3074047A2 (en) * | 2013-11-26 | 2016-10-05 | The Brigham and Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270961B1 (en) * | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US5128247A (en) * | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
| US5130423A (en) * | 1990-07-13 | 1992-07-14 | Microprobe Corporation | Non-corrosive compositions and methods useful for the extraction of nucleic acids |
| CA2155186A1 (en) * | 1993-02-01 | 1994-08-18 | Kevin M. Ulmer | Methods and apparatus for dna sequencing |
| JPH08509606A (ja) * | 1993-04-20 | 1996-10-15 | ロビンソン，ウィリアム エス． | 細胞内感染因子に感染した個体を処置する方法および物質 |
| US5945515A (en) * | 1995-07-31 | 1999-08-31 | Chomczynski; Piotr | Product and process for isolating DNA, RNA and proteins |
| ATE389712T1 (de) * | 1997-01-31 | 2008-04-15 | Edward P Cohen | Krebs immuntherapie mit semi-allogenen zellen |
| DE19740571C1 (de) * | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
| US6316193B1 (en) * | 1998-10-06 | 2001-11-13 | Origene Technologies, Inc. | Rapid-screen cDNA library panels |
| US20020015950A1 (en) * | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
| US20040018188A9 (en) | 1999-01-20 | 2004-01-29 | Incyte Genomics, Inc. | Sparc-related proteins |
| US6387664B1 (en) * | 1999-02-26 | 2002-05-14 | Secretary Of Agency Of Industrial Science And Technology | Sparc fusion protein and method for producing the same |
| AU7607900A (en) | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| JP2003530893A (ja) | 2000-04-25 | 2003-10-21 | ディーエヌエー サイエンシーズ インコーポレーテッド | ポリメラーゼのプルーフリーディング活性によるヌクレオチド配列変異の検出 |
| WO2004005883A2 (en) | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| WO2002090544A2 (en) * | 2001-05-04 | 2002-11-14 | Hybrigenics | Protein-protein interactions in adipocyte cells (3) |
| US6919504B2 (en) * | 2002-12-19 | 2005-07-19 | 3M Innovative Properties Company | Flexible heat sink |
| CA2513251C (en) * | 2003-01-14 | 2013-03-19 | Dana-Farber Cancer Institute | Cancer therapy sensitizer |
| US20070178090A1 (en) * | 2003-04-01 | 2007-08-02 | Genzyme Corporation | Breast endothelial cell expression patterns |
| CN1980699B (zh) | 2004-05-14 | 2012-03-21 | 阿布拉西斯生物科学公司 | 利用白蛋白-结合蛋白作为靶标的治疗方法 |
-
2006
- 2006-02-17 WO PCT/US2006/005615 patent/WO2006112930A2/en not_active Ceased
- 2006-02-17 JP JP2007556317A patent/JP2008535475A/ja active Pending
- 2006-02-17 EP EP06769757A patent/EP1869077A2/en not_active Ceased
- 2006-02-17 AU AU2006237613A patent/AU2006237613A1/en not_active Abandoned
- 2006-02-17 US US11/356,829 patent/US7332568B2/en active Active
- 2006-02-17 CA CA2598510A patent/CA2598510C/en not_active Expired - Fee Related
- 2006-02-17 CN CNA200680012446XA patent/CN101160321A/zh active Pending
-
2007
- 2007-12-26 US US11/964,390 patent/US20080182258A1/en not_active Abandoned
-
2010
- 2010-09-10 US US12/879,575 patent/US20110009337A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535475A5 (enExample) | ||
| US11466085B2 (en) | Anti-PD-L1 nanobody, coding sequence and use thereof | |
| CN111683968B (zh) | 结合至cd137和psma的分子 | |
| CN112480253B (zh) | 一种抗pd-l1纳米抗体及其衍生物和用途 | |
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| JP7690285B2 (ja) | 結合タンパク質１ | |
| JP7097636B2 (ja) | 抗Ｈｅｒ２ナノボディ及びそのコード序列と用途 | |
| CN108473590B (zh) | 治疗分子 | |
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| JP2003284577A (ja) | 癌マーカー用生物合成結合蛋白質 | |
| JP7691720B2 (ja) | 抗ヒトｃｄ７３抗体およびその適用 | |
| CN105829343A (zh) | Gitr抗原结合蛋白 | |
| WO2016112855A1 (zh) | 抗cd19单克隆抗体及其制备方法 | |
| CA2598510A1 (en) | Q3 sparc deletion mutant and uses thereof | |
| CN112794911B (zh) | 人源化抗叶酸受体1抗体及其应用 | |
| CN114106190A (zh) | 一种抗vegf/pd-l1双特异性抗体及其用途 | |
| RS58448B1 (sr) | Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba | |
| CN117304315B (zh) | 抗il-6的纳米抗体及其在il-6相关疾病中的应用 | |
| CN111148759A (zh) | 结合至纤维连接蛋白b结构域的蛋白 | |
| JP2020535110A (ja) | 分子誘導システムペプチド及びその使用 | |
| CN113461825A (zh) | 一种抗pd-l2纳米抗体及其应用 | |
| CN120383679A (zh) | 抗FAP单域抗体、Fc融合蛋白、免疫缀合物及其应用 | |
| JP2024508886A (ja) | 抗体－オリゴヌクレオチドコンジュゲートを使用した標的化の増強 | |
| CN117659194A (zh) | 靶向egfr的纳米抗体、药物偶联物及其用途 | |
| WO2023116781A1 (zh) | 一种新型pd1单域抗体的开发 |